Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects

Study identifier:H8O-EW-GWCI

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Placebo- and Positive-Controlled Study of the Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects

Medical condition

Healthy subjects

Phase

Phase 1

Healthy volunteers

Yes

Study drug

exenatide, exenatide, exenatide, exenatide, exenatide, exenatide, Moxifloxacin, Moxifloxacin, Moxifloxacin, Moxifloxacin, Moxifloxacin, Moxifloxacin, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo

Sex

All

Actual enrollment

70

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Apr 2008
Primary Completion Date: 01 Jul 2008
Study Completion Date: 01 Jul 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Eli Lilly and Company

Inclusion and exclusion criteria